Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy

W Qi, S Zhao, J Chen - Future Oncology, 2020 - Taylor & Francis
Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in
advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac …
被引用次数：7 相关文章

Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy

Q Wei-xiang, S Zhao, J Chen - Future Oncology, 2020 - search.proquest.com
Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in
advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac …

Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy

WX Qi, S Zhao, J Chen - Future oncology (London …, 2020 - pubmed.ncbi.nlm.nih.gov
Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in
advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac …

Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy.

WX Qi, S Zhao, J Chen - Future Oncology (London, England), 2020 - europepmc.org
Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in
advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac …

Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy

W Qi, J Chen - 2019 - researchsquare.com
Background Panitumumab, a novel anti-epidermal growth factor receptor (EGFR)
monoclonal antibody (mAb), has been approved for the treatment of advanced colorectal …

Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy

W Qi, J Chen - 2019 - europepmc.org
Background: Panitumumab, a novel anti-epidermal growth factor receptor (EGFR)
monoclonal antibody (mAb), has been approved for the treatment of advanced colorectal …